As a leading enterprise in innovative traditional Chinese medicine, Kangyuan Pharmaceutical has always actively focused on scientific research and innovation, intelligent manufacturing, and compliant operations, deepening reforms in various aspects of company management and actively practicing high-quality development. As an innovative traditional Chinese medicine enterprise, Kangyuan Pharmaceutical has always regarded research and development as the top priority for the company's development. Wang Zhenzhong, vice chairman of Kangyuan Pharmaceutical and executive president of Modern Chinese Medicine Research Institute, said that Kangyuan has built several scientific research bases in Lianyungang, Nanjing, Shanghai and other places. It has built national key laboratories for Chinese medicine pharmaceutical process control and intelligent manufacturing technology, national and local joint engineering research centers for traditional Chinese patent medicines and simple preparations intelligent manufacturing and other national scientific research platforms. It has more than 600 invention patents, undertakes more than 40 major scientific and technological projects at the national and provincial levels, has 53 new Chinese medicines, and has won one second prize for national technological invention, three second prizes for national scientific and technological progress, and two gold prizes for Chinese patents. It has been ranked first in the "Ranking List of Chinese Traditional Medicine Research and Development Strength" for many consecutive years. In terms of technological innovation, Kangyuan Pharmaceutical has always considered it from the perspective of traditional Chinese medicine innovation leading the medical revolution, constantly releasing new driving forces for technological innovation and development. After years of effort and based on a national level scientific research platform, Kangyuan Pharmaceutical has made many industry breakthroughs: creating an intelligent manufacturing technology system with functional ingredient groups as the key quality goal, and breaking through key technologies. From a company perspective, it is based on the demand for high-quality and healthy business development; From an industry perspective, professional academia is also the mission and value of pharmaceutical practitioners Yang Yongchun, General Manager of Kangyuan Pharmaceutical, said. The reason why there is a need for business development is because the series of scientific theories, scientific research innovations, and new technology applications of Kangyuan products need to be understood by more medical practitioners. Kangyuan put forward the decoding theory of traditional Chinese patent medicines and simple preparations with functional substances as the core for the first time in the industry, providing a theoretical basis for "what to control" and "how to control" in the pharmaceutical process of traditional Chinese medicine. For example, our 'decoding traditional Chinese medicine', 'identification of functional ingredient groups', and' intelligent manufacturing of traditional Chinese medicine based on whole process quality control 'ensure the effectiveness, stability, and consistency of drugs through these theoretical technologies. Familiarizing and explaining these theoretical points will give frontline practitioners more confidence in dealing with diseases. We need to use modern scientific and easy to understand language to interpret the principles of innovative traditional Chinese medicine. From an industry perspective, our customers are healthcare professionals and patients. Our product needs to be professionally and accurately introduced to frontline clinical personnel, and Kangyuan's innovative traditional Chinese medicine is not only aimed at traditional Chinese medicine doctors, but also at a wider range of Western medicine doctors. We need to explain and clarify the efficacy of traditional Chinese medicine to them, accurately convey Kangyuan's exclusive academic information and clinical value of innovative traditional Chinese medicine to doctors, and help both traditional Chinese medicine and Western medicine doctors better understand and recognize innovative traditional Chinese medicine. At the same time, Kangyuan regards improving employee quality as another effective path for academic exploration, relying on the company's internal "Dr. Pan Project" to provide regular, systematic, and professional academic training for frontline employees. Through the learning of Dr. Pan's engineering, all internal employees of the company have gained a lot. Frontline colleagues in the market have used this academic and professional platform to continuously transform into providers of innovative pharmaceutical information and the best diagnosis and treatment solutions for Kangyuan through their own learning, "said Pan Yu, Deputy General Manager of Kangyuan Pharmaceutical. It is reported that the "Dr. Pan Project" has now developed to an upgraded version, and the academic literacy of frontline employees has also been significantly improved. Kangyuan's exclusive innovative academic information and clinical value of traditional Chinese medicine are also being transmitted to frontline practitioners in the medical industry at the first time. With strong scientific research capabilities and outstanding academic abilities, Kangyuan has decided to continue advancing the reform to a deeper level. In Kangyuan, a deeper level of reform is comprehensive compliance. At Kangyuan, compliance is genetic Yang Yongchun, General Manager of Kangyuan Pharmaceutical, introduced it. Compliance construction is not only necessary for the modern nature of Kangyuan's enterprise, but also the only way to comprehensively build new quality marketing capabilities. For compliance construction, Kangyuan always insists on putting compliance in the forefront and consolidating the foundation of innovative development. The comprehensive compliance upgrade is a major reform that focuses on the future, so this process can be said to be difficult, and the pain of reform also puts a lot of pressure on enterprises. We are one of the companies that are firmly committed to promoting comprehensive compliance in the pharmaceutical market, with strong academic and innovative support. We will continue to persist and work hard to the end Yang Yongchun said that Kangyuan now focuses on academic research with its left hand and market cultivation with its right hand, and strictly controls the standardized governance of listed companies, achieving a new level of marketing model upgrading and compliance transformation. "We collectively refer to this process as building a new quality marketing power in the traditional Chinese medicine market." From scientific research to intelligent manufacturing to compliance management, it can be said that every link is closely related to the fate of the enterprise. Yang Yongchun stated that we are integrating various advantageous resources of the enterprise to promote high-quality development, and also hope to contribute new momentum to the sustainable development of the industry and society through our own efforts. (New Society)